| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |